Galenica AG Q2 2026 Earnings Recap

Shares declined 2.9% as investors appeared cautious despite stable top-line sales growth and margin expansion, likely reflecting concerns about the ongoing structural changes and potential margin pressures in the homecare segment and pharmacy production shutdown.

Key Takeaways

• Revenue increased 7.1% to CHF 2.136 billion in H1 2026, with adjusted EBIT up 7.1% to just under CHF 118 million; adjusted for prior one-offs, EBIT growth was 12.6%.
• The company reaffirmed full-year guidance but highlighted ongoing seasonal effects and strategic restructuring, including the planned discontinuation of Bichsel’s pharmaceutical production by end-2026.
• Homecare segment restructuring aims to integrate Bichsel and Lifestage Solutions for a more focused growth model, with investments in automation and patient-tailored medication services.
• Expansion of healthcare consultation services and rollout of new in-store concepts have driven a 27% increase in fee-paying consultations; vaccination services are growing and expected to be reimbursed by basic health insurance in 2027.
• Management emphasized long-term market shifts relating to online sales liberalization, expected no earlier than 2029, and the company’s investments into omnichannel and digital tools like Prescription Manager to maintain customer loyalty.